<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03546452</url>
  </required_header>
  <id_info>
    <org_study_id>shanghai Chest 0014</org_study_id>
    <nct_id>NCT03546452</nct_id>
  </id_info>
  <brief_title>A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC</brief_title>
  <official_title>A Prospective Study to Evaluate the Results of Different NGS- Panels in Mutation Detection and Tumor Mutation Burden(TMB) Calculation by Using Malignant Hydrothorax From NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sinotech Genomics Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amoy Diagnostics Co., LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Burning Rock Medical Examination Institute Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Geneplus-Beijing Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berry Genomics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective study to evaluate consistency of different NGS-panel. Cell free DNA is purified
      from each malignant hydrothorax from NSCLC .Different NGS-panels are applied to perform in
      vitro diagnosis to detect Single Nucleotide Variants(SNV) and to calculate TMB value in these
      DNA samples.Consistency of enrolled NGS-panels are then evaluated by statistical analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Chest Hospital in accordance with the clinical requirements of the treatment required to
           extract ML hydrothorax sent to hospital pathology department for exfoliated Cell
           diagnosis and production of cell wax block, while the additional responsibility for the
           extraction of hydrothorax 500ml, and collect 10ml venous blood sample, Venous blood
           samples are stored in either the A cell-free DNA Blood collection Tube (STRECK tube) or
           the ethylenediaminetetraacetic acid(EDTA) anticoagulant tube.

        2. Amoy Diagnostics Co., Ltd. (AmoyDx) is responsible for plasma separation after sampling
           2 hours, plasma is frozen by the chest Hospital, AmoyDx completes the purification of
           peripheral blood cells genomic DNA , and which is divided into 6 parts ,5 of which are
           send to in vitro diagnostic products (IVD) enterprises to perform NGS-Panel detection.

        3. 100ml hydrothorax is send to each IVD enterprise.

        4. Each IVD enterprise carries on the hydrothorax cell free DNA and peripheral blood cell
           genomic DNA NGS-Panel detection according to their own protocol.

        5. Each IVD enterprise will complete the test within 7-10 working days and fill out the
           results in accordance with the report template provided by this research project
           (provided by Guangzhou Burning Rock Medical Examination Institute Co., Ltd.) and submit
           to sponsor by email.

        6. Sponsor would use whole exon panel (WES) to obtain an TMB value if needed.

        7. Employ four-grid analysis to evaluate positive compliance rate, negative compliance
           rate, total compliance rate of all submitted data.

        8. Employ kappa test to evaluate the consistency of each two detections.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 18, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate consistency of TMB value of different NGS-Panel</measure>
    <time_frame>5 months</time_frame>
    <description>All DNA samples were tested to calculate TMB value by all enrolled NGS-panel (include WES if necessary), each sample is then to be marked as TMB high, TMB median or TMB low according to the cutoff value identified by different IVD enterprises.
Employ Cohen's kappa test to calculate the kappa value to measures inter-rater agreement for categorical result.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malignant Hydrothorax</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>malignant NSCLC hydrothorax</arm_group_label>
    <description>cell free DNA ,which is purified from malignant NSCLC hydrothorax, tested by in vitro NGS-panel</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>in vitro NGS-panel</intervention_name>
    <description>cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel</description>
    <arm_group_label>malignant NSCLC hydrothorax</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cell block obtain from malignant NSCLC hydrothorax
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients in shanghai chest hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced malignant lung cancer, with treatment of pleural effusion, hydrothorax volume
             not less than 800ml

        Exclusion Criteria:

          -  The sample size is not sufficient to detect.

          -  There are not enough tumor cells in the tissue section to be evaluated through the
             pathology department of the chest Hospital.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>shun lu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>shun lu, Prof.</last_name>
    <phone>021-2220000</phone>
    <email>shun_lu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yongfeng yu, Prof.</last_name>
    <phone>18017321559</phone>
    <email>yuyongfeng212@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shangha Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yongfeng yu</last_name>
      <phone>18017321559</phone>
      <email>yuyongfeng212@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>June 5, 2018</last_update_submitted>
  <last_update_submitted_qc>June 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Lu Shun</investigator_full_name>
    <investigator_title>Shanghai Chest Hospital</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>malignant hydrothorax</keyword>
  <keyword>prospective study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrothorax</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

